NFKB1 and colorectal carcinoma: In summary, our discovery unveils a novel mechanism that (S)-2,3-epoxysqualene-dependent NF-κB activation promotes 5-FU resistance of CRC, which establishes the first association between a metabolic intermediate of cholesterol metabolism and the NF-κB pathway.